0000000000294901

AUTHOR

Kevin Bouiller

0000-0002-2177-4318

showing 9 related works from this author

No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia

2018

International audience; The vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. In this study, the outcomes of patients with MSSA bacteraemia with a vancomycin MIC ≥ 1.5 mg/L were assessed. A prospective cohort of patients with MSSA bacteraemia in two tertiary-care hospitals was collected. The vancomycin MIC was determined by Etest. Staphylococcus aureus strains were categorised as low (<1.5 mg/L) or high (≥1.5 mg/L) vancomycin MIC. First- and second-line treatments were recorded and classified as optimal, appropriate and inappropriate. The primary endpoint was 30-day mortality. A total o…

0301 basic medicineMicrobiology (medical)MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyStaphylococcus aureusmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsBacteremiaMicrobial Sensitivity Testsmedicine.disease_cause03 medical and health sciencesMinimum inhibitory concentrationVancomycin[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineHumansPharmacology (medical)Prospective StudiesMortalityProspective cohort studyEtestDialysisAgedAged 80 and overMinimum inhibitory concentrationbusiness.industryGeneral MedicineMiddle AgedStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycoses3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesStaphylococcus aureusCatheter-Related InfectionsVancomycinBacteraemiaFemaleMethicillin Susceptible Staphylococcus Aureusbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Review of European and American guidelines for the diagnosis of Lyme borreliosis

2019

International audience; Lyme disease is a tick-borne bacterial disease with polymorphic clinical manifestations (cutaneous, rheumatological, and neurological). In recent years the issue of the diagnosis of this infection has been highly publicized on the Internet and other media in Europe and America. Some patients and physicians may share the perception that the diagnosis of the infection is not reliable in France. We reviewed current European and American guidelines on Lyme disease and performed a methodological evaluation of all guidelines. We retrieved 16 guidelines from seven countries. Our analysis revealed a global consensus regarding diagnosis at each stage of the infection. All gui…

medicine.medical_specialtyDiagnostic methodsRecommandationsGuidelinesSerologyDiagnosis Differential03 medical and health sciencesLyme disease[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesBorreliamedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyComputingMilieux_MISCELLANEOUSLyme Disease[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesBacterial diseasebiology030306 microbiologyLyme borreliosisbusiness.industryBorreliabiology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyUnited States3. Good healthLYMEEuropeInfectious DiseasesFamily medicinePractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyLymeErythema migransbusinessMédecine et Maladies Infectieuses
researchProduct

Unconventional diagnostic tests for Lyme borreliosis: a systematic review

2019

Abstract Background Lyme borreliosis (LB) diagnosis currently relies mainly on serological tests and sometimes PCR or culture. However, other biological assays are being developed to try to improve Borrelia-infection diagnosis and/or monitoring. Objectives To analyse available data on these unconventional LB diagnostic assays through a systematic literature review. Methods We searched PubMed and Cochrane Library databases according to the PRISMA-DTA method and the Cochrane Handbook for Systematic Reviews of Interventions. We analysed controlled and uncontrolled studies (published 1983–2018) on biological tests for adults to diagnose LB according to the European Study Group for Lyme Borrelio…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty030106 microbiologyClinical assessmentMEDLINEReviewCochrane LibrarySensitivity and SpecificitySerology03 medical and health sciences0302 clinical medicineMeta-Analysis as Topic[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineHumansSerologic Tests[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030212 general & internal medicineIntensive care medicineComputingMilieux_MISCELLANEOUSLyme borreliosisLyme Disease[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesClinical Laboratory TechniquesLyme borreliosisbusiness.industryDiagnostic testGeneral Medicinemedicine.diseasebacterial infections and mycoses[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthInfectious DiseasesSystematic reviewDiagnostic testsBorrelia burgdorferi[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyXenodiagnosesbusinessNeuroborreliosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Functional signs in patients consulting for presumed Lyme borreliosis

2019

Little is known about the functional symptoms associated with Lyme borreliosis (LB) in Europe. We aimed to assess functional symptoms associated with presumed LB and to compare patients with and without confirmed LB.We performed a retrospective monocenter study. Patients consulting for presumed LB were included.Between November 2015 and June 2018, 355patients were included (mean age: 51years, 52% of women) of which 48had LB: erythema migrans (42%), early disseminated LB (50%; 35% of neuroborreliosis cases), and late disseminated LB (8%). The most frequently reported functional symptoms were neuropathic pain (23%), arthralgia (23%), and asthenia (17%). Other functional symptoms were rare (≤1…

AdultMalemedicine.medical_specialtyFunctional symptomsDiagnosis Differential03 medical and health sciencesLyme diseasemedicineHumansLyme NeuroborreliosisLyme diseaseIn patientSerologic TestsReferral and ConsultationAgedRetrospective StudiesLyme borreliosis0303 health sciences030306 microbiologyLyme borreliosisbusiness.industryMean ageMiddle Agedmedicine.diseaseDermatology3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesTreatment OutcomeBorrelia burgdorferiNeuropathic painErythema migransErythema Chronicum MigransFemaleFranceSymptom AssessmentbusinessNeuroborreliosis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

2022

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing como…

EğitimSocial Sciences and HumanitiesInformation Security and ReliabilitySocial Sciences (SOC)Sosyal Bilimler ve Beşeri BilimlerEpidemiologyEDUCATION & EDUCATIONAL RESEARCHTemel Bilimler (SCI)BİLGİSAYAR BİLİMİ BİLGİ SİSTEMLERİMATHEMATICSSociology[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesProspective StudiesCOMPUTER SCIENCE INFORMATION SYSTEMSSTATISTICS & PROBABILITYMatematikBilgisayar Bilimi UygulamalarıComputer SciencesBilgi Güvenliği ve GüvenilirliğiEĞİTİM VE EĞİTİM ARAŞTIRMASIBİLGİ BİLİMİ VE KÜTÜPHANE BİLİMİBilgi sistemiComputer Science ApplicationsKütüphane ve Bilgi BilimleriHospitalizationNatural Sciences (SCI)Physical SciencesEngineering and TechnologySosyal Bilimler (SOC)Bilgisayar BilimiStatistics Probability and UncertaintyInformation SystemsHumanStatistics and ProbabilityHumans; Pandemics; Prospective Studies; SARS-CoV-2; COVID-19; HospitalizationSOCIAL SCIENCES GENERALLibrary and Information SciencesEducationSDG 3 - Good Health and Well-beingLibrary SciencesINFORMATION SCIENCE & LIBRARY SCIENCEİstatistik ve OlasılıkHumansSosyal ve Beşeri BilimlerBilgisayar BilimleriSocial Sciences & HumanitiesEngineering Computing & Technology (ENG)SosyolojiPandemicsPandemicSARS-CoV-2İSTATİSTİK & OLASILIKCOVID-19Mühendislik Bilişim ve Teknoloji (ENG)İstatistik Olasılık ve BelirsizlikSosyal Bilimler GenelCOMPUTER SCIENCEProspective StudieFizik BilimleriViral infectionMühendislik ve TeknolojiKütüphanecilik
researchProduct

Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?

2018

In this study, the activity of 18 non-carbapenem antibiotics was evaluated against 100 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) and 50 ESBL-producing Klebsiella pneumoniae (ESBL-Kp) isolated from urinary tract infections and bacteraemia in 2016. Minimum inhibitory concentrations (MICs) were determined using reference methods and the susceptibility profiles were defined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017 recommendations. All of the ESBL-Ec isolates were susceptible to ceftazidime/avibactam and a great majority of them were susceptible to fosfomycin (98%), piperacillin/tazobactam (97%), amikacin (97%) and nitr…

0301 basic medicineKlebsiella pneumoniaePenicillanic AcidCeftazidimeCeftazidimechemistry.chemical_compoundAntibiotics[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitologypolycyclic compoundsPharmacology (medical)biologyEnterobacteriaceae InfectionsGeneral MedicineAnti-Bacterial Agents3. Good healthDrug CombinationsKlebsiella pneumoniaeInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAmikacinUrinary Tract InfectionsCeftolozanemedicine.drugMicrobiology (medical)TazobactamAvibactam030106 microbiologyMicrobial Sensitivity TestsTazobactambeta-LactamasesMicrobiology03 medical and health sciencesEnterobacteriaceaemedicineEscherichia coliHumansMecillinambusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCephalosporinsAlternativesCarbapenemschemistryESBLSusceptibilitybacteriabusinessAzabicyclo CompoundsPiperacillin
researchProduct

Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial

2021

Background: The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in patients with COVID-19 requiring oxygen and/or ventilator support. Methods: In this European multicentre, open-label, parallel-group, randomised, controlled trial in adults hospitalised with COVID-19 (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard of care alone or in combination with intravenous remdesivir (200 mg on day 1, then 100 mg once-daily for 9 days or until discharge). Treatment assignation was performed via web-based randomisation stratified on illness severity and administrative European regio…

education.field_of_studymedicine.medical_specialtybusiness.industryPopulationDeclarationCommissionTreatment and control groupsInformed consentFamily medicineHealth caremedicinemedia_common.cataloged_instanceEuropean unioneducationbusinessPsychology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDeclaration of Helsinkimedia_commonSSRN Electronic Journal
researchProduct

Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-S…

2022

International audience; No abstract available

Microbiology (medical)0303 health sciences2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)030306 microbiologybusiness.industryHost (biology)medicine.drug_classSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Monoclonal antibodyVirology03 medical and health sciences0302 clinical medicineInfectious DiseasesMedicine030212 general & internal medicinebusiness
researchProduct

The value of open-source clinical science in pandemic response

2021

International audience

Biomedical Research[SDV]Life Sciences [q-bio]Clinical scienceGlobal HealthCorrectionsMicrobiology1117 Public Health and Health Services1108 Medical MicrobiologyPandemicEconomicsHumansISARIC Clinical Characterisation GroupPandemicsCOVID-19/epidemiologyActuarial scienceInformation DisseminationSARS-CoV-2CommentISARICCOVID-191103 Clinical SciencesCommunicable Disease Control/methodsInfectious DiseasesOpen sourceCommunicable Disease ControlCOVID-19; Communicable Disease Control; Global Health; Humans; SARS-CoV-2; Biomedical Research; Information Dissemination; PandemicsValue (mathematics)HumanThe Lancet Infectious Diseases
researchProduct